Company

BioGene Pharmaceutical

As of the edition of 20 October 2026, BioGene Pharmaceutical runs 1 drug; it is on route A at 7 targets and on route B at 0 targets.

Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.

Drugs by status

StatusCount
Stopped1
Total1

Where it needs a new molecule

Route A at 7 targets, route B at 0 targets.

Three of its 7 rows, by target and route
TargetRoute
CSF1R Macrophage colony-stimulating factor 1 receptorRoute A
KDR Vascular endothelial growth factor receptor 2Route A
FLT4 Vascular endothelial growth factor receptor 3Route A

All 7 rows on route A or B

In the product

7 company-target rows on route A or B; 4 are not shown here, and no score is.

Where its trials are

  • Pregnancy and women's health: 1 trials led
  • Urinary and reproductive: 1 trials led